CD274 and lung carcinoma: Moreover, both TILs and PD-L1 expression have been extensively studied and reported as significant biomarkers, particularly relevant in predicting the response to immune checkpoint inhibitors (ICIs), thereby highlighting their essential role in shaping therapeutic strategies and advancing personalized medicine approaches in lung cancer [25,26,27,28,29,30].